Letter: choosing between ustekinumab and vedolizumab in anti-TNF refractory Crohn's disease-the devil is in the detail

Aliment Pharmacol Ther. 2020 Aug;52(3):561-562. doi: 10.1111/apt.15862.

Authors

Ashish Srinivasan^{1

2

3}, Peter De Cruz^{1

4}, Daniel R van Langenberg^{1

3}

Affiliations

¹ Department of Gastroenterology, Eastern Health, Melbourne, Vic., Australia.
² Department of Gastroenterology, Austin Health, Melbourne, Vic., Australia.
³ Department of Medicine, Monash University, Melbourne, Vic., Australia.
⁴ Department of Medicine, Austin Academic Centre, University of Melbourne, Melbourne, Vic., Australia.

PMID: 32656826
DOI: 10.1111/apt.15862

No abstract available

Publication types

Letter
Comment

MeSH terms

Antibodies, Monoclonal, Humanized
Crohn Disease*
Humans
Tumor Necrosis Factor-alpha
Ustekinumab*

Substances

Antibodies, Monoclonal, Humanized
Tumor Necrosis Factor-alpha
vedolizumab
Ustekinumab